Clinical trials: Hematological Neoplasm
Hematologic Neoplasms
A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies
The primary objective of this study is to characterize the safety, tolerability, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD) of relatlimab administered alone or in combination with nivolumab to subjects with…
- Trial name
- NCT02061761
- Testing
- BMS-986016, BMS-936558
- Where
- 10 sites in United States, Canada
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies
A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies
- Trial name
- NCT04532203
- Testing
- CAR-T cells, Ommaya Reservoir
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Zhejiang University
Cognitive Impairment, Haematological Malignancy
Cognitive Status Assessment In Elderly Patients With Active Treatment For Haematological Malignancies
BACKGROUND Neurocognitive symptoms have a high prevalence in cancer patients, resulting in a significant impact on daily life and tolerance to therapy.
- Conditions
- Cognitive Impairment, Haematological Malignancy, Chemo-brain
- Trial name
- NCT04673305
- Testing
- Cognitive Assessment, Cytokine dosage
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Ospedale San Carlo Borromeo
Breast Cancer, Cancer
IIT2020-20-SHIRAZIP-WALK: Nature Walks
The purpose of this study is to examine whether nature-based activities provide benefits for breast cancer survivors. The investigators want to know whether a nature-based exercise program is feasible.
- Conditions
- Breast Cancer, Cancer, Lymphoma, Leukemia
- Trial name
- NCT04896580
- Testing
- Nature based exercise
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
This pilot phase I trial studies the side effects of engineered donor stem cell transplant in treating patients with hematologic malignancies.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Aplastic Anemia
- Trial name
- NCT02960646
- Testing
- Cyclophosphamide, Filgrastim, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Myeloproliferative Disorders, Blood Cancer
TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD
To evaluate the feasibility and safety of TLI/ATG conditioning for allogeneic HCT for elderly patients with advanced stage MDS and MPD.
- Conditions
- Myeloproliferative Disorders, Blood Cancer, Myelodysplastic Syndromes
- Trial name
- NCT00185796
- Testing
- Total Lymphoid Irradiation (TLI), Anti-Thymocyte Globulin as Conditioning (ATG)
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Stanford University
Hematologic Malignancies, Disorder Related to Transplantation
Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen
In this study, participants with high-risk hematologic malignancies undergoing hematopoietic cell transplantation (HCT), who do not have a suitable human leukocyte antigen (HLA)-matched related/sibling donor (MSD), matched…
- Conditions
- Hematologic Malignancies, Disorder Related to Transplantation, Hematopoietic Malignancy
- Trial name
- NCT01328496
- Testing
- Preparative Regimen
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- St. Jude Children's Research Hospital
B-Cell Lymphoblastic Leukemia/Lymphoma
CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors
This study is a multi-center, open, prospective single-arm clinical study of patients with relapsed / refractory B cell hematological tumors to evaluate the safety and efficacy of CD19 \& CD20 bispecific CAR-T cells in relapsed /…
- Trial name
- NCT06503094
- Testing
- CD19&CD20 bispecific CAR-T cells
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Multiple Myeloma
Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies
This is a multi-center, open-label, dose escalation, Phase 1 study of oral LGH447 in Japanese patients with relapsed and/or refractory multiple myeloma for which no standard effective treatment options exist.
- Trial name
- NCT02160951
- Testing
- LGH447
- Where
- 4 sites in Japan
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Hematologic Malignancy, Patient Education
Effect of Mobile Application on Supportive Care Needs and Quality of Life Patients Undergoing Hematopoietic Stem Cell Transplantation
The aim of this interventional study is to determine the effect of the mobile application on quality of life and supportive care in patient undergoing stem cell transplantation.The main questions it aims to answer are: 1.
- Trial name
- NCT05609227
- Testing
- mobile application
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people
- Sponsor
- Baskent University
Hematopoietic and Lymphoid Cell Neoplasm
A Multidisciplinary Approach to Improve the Health of Older Adults With Blood Cancers After Stem Cell Transplantation
This clinical trial studies the usefulness and process of a multidisciplinary intervention, where patients see multiple healthcare professionals, aimed at improving fitness and the ability to bounce back after transplant for…
- Trial name
- NCT04914338
- Testing
- Health Promotion, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- City of Hope Medical Center
Hematologic Malignancies
Safety of Romiplostim (Nplate®) Following UCBT
This is a single institution, phase I dose escalation study of weekly romiplostim post umbilical cord blood transplantation in patients who fail to achieve platelet engraftment by day +30.
- Trial name
- NCT02046291
- Testing
- Romiplostim
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Stem Cell Transplantation, Immunotherapy
Rehabilitation Needs for Hematologic Cancer Candidate for Hematopoietic Stem Cell Transplantation or CAR T-Cell Therapy
Hematopoietic Stem Cell Transplantation (HSCT) and CAR T-cell therapy are effective treatments for blood cancers, extending patients lives. However, these treatments can cause side effects like muscle weakness and fatigue.
- Conditions
- Stem Cell Transplantation, Immunotherapy, CAR T-Cell Therapy
- Trial name
- HEMATOneeds (NCT06506396)
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- University of Modena and Reggio Emilia
Pediatric Solid Malignancies, Pediatric Hematological Malignancies
Neutrophil Extracellular Traps (NETs) Formation Following Chemotherapy and Their Role in Antitumor Activity
Examine neutrophil extracellular traps (NETs) formation, in relation to other neutrophil functions like chemotaxis, superoxide production, hydrogen peroxide production, and the presence of myeloperoxidase, in pediatric patients…
- Trial name
- NCT01533779
- Where
- Israel
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Blastic Plasmacytoid Dendritic Cell Neoplasm, Hematological Malignancies
Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease characterized by an aggressive clinical behavior and a poor prognosis.
- Trial name
- LpDC (NCT02859623)
- Volunteers
- 86 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Umbilical Cord Blood, Stem Cell Transplantation
Allogenic Transplantation of Ex-vivo Expanded Cord Blood (CB)
The aim of this study is to evaluate the safety profile and tolerability of infusion of cord blood cells expanded in the lab and to evaluated whether through the infusion of expanded cells it is possible to expedite engraftment…
- Conditions
- Umbilical Cord Blood, Stem Cell Transplantation, Hematological Malignancies
- Trial name
- NCT01235468
- Testing
- ex vivo expansion
- Sponsor
- Dr. Avichai Shimoni MD
Leukemia, Lymphocytic, Acute, Leukemia, Nonlymphocytic, Acute
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
This study primarily determined the safety and tolerability of escalating doses of vosaroxin (SNS-595) in 2 dose schedules, and assessed the PK profile of vosaroxin and defined a recommended dose regimen for Phase 2 studies.
- Conditions
- Leukemia, Lymphocytic, Acute, Leukemia, Nonlymphocytic, Acute, Leukemia, Myeloid, Chronic, Myelodysplastic Syndromes
- Trial name
- NCT00246662
- Testing
- Vosaroxin
- Where
- 5 sites in United States
- Volunteers
- 75 people
- Sponsor
- Sunesis Pharmaceuticals
Hematological Malignancies
National Longitudinal Cohort of Hematological Diseases (NICHE) - CART
This is a multicenter, ambispective, longitudinal, observational cohort study investigating CAR-T cell therapy in Chinese patients with hematological malignancies.
- Trial name
- NCT06607289
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Luspatercept, Epoetin
Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for hematological malignancies. Nonetheless, poor graft function remains a life-threatening complication after allo-HSCT.
- Conditions
- Luspatercept, Epoetin, Poor Erythroid Engraftment, Hematological Malignancies
- Trial name
- NCT07636486
- Testing
- Luspatercept, Epoetin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hematologic Diseases
Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies
To determine the safety, toxicity, and maximum tolerated dose (MTD) of CD19/CD20 bispecific CAR-T cells with 4-1BB and mutated CD28 costimulatory domains (20-19 Tan BB06z) in patients with relapsed or refractory CD19+ aggressive…
- Trial name
- NCT07701889
- Testing
- 20-19 Tan BB06oz CAR T
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Roswell Park Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.